Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:3/26/2009

PALO ALTO, Calif., March 26 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the fourth quarter and full year ended December 31, 2008.

Total revenues for the quarter ended December 31, 2008 were $19.6 million, compared to $15.5 million for the quarter ended December 31, 2007. Total revenues for the year ended December 31, 2008 were $67.5 million, compared to $65.3 million for the year ended December 31, 2007. Total revenues for 2008 included contract revenue of $1.1 million, compared to $10.6 million for 2007, which included $9.5 million of milestone payments from UCB Pharma Limited. A $10.0 million milestone payment received in 2008 from UCB Pharma Limited will be recorded as contract revenue in 2009.

XYREM(R) (sodium oxybate) oral solution net sales increased 42% to $15.8 million for the quarter ended December 31, 2008, compared to sales of $11.1 million for the quarter ended December 31, 2007. XYREM net sales for the year ended December 31, 2008 increased 38% to $53.8 million, compared with $39.0 million for the year ended December 31, 2007. Net sales of once-daily LUVOX CR(R) (fluvoxamine maleate) Extended-Release Capsules, launched in April 2008, were $3.1 million for the fourth quarter of 2008 and $5.7 million for the nine-month period since launch.

Research and development expenses for the quarter ended December 31, 2008 were $14.7 million, compared to $20.5 million for the quarter ended December 31, 2007. For the year ended December 31, 2008, research and development expenses were $70.0 million, compared to $69.8 million for the year ended December 31, 2007. Research and development expenses in both 2008 and 2007 primarily reflect the expenses relating to the Phase III clinical activities for the company's JZP-6 (sodium oxybate for the treatment of fibromyalgia) product candidate. Lower expenses in the fourth quarter of 2008 also reflect a reduced level of activity on development programs other than JZP-6, pending partnering or other funds to pursue future development of those programs.

Selling, general and administrative expenses for the quarter ended December 31, 2008 were $20.2 million, compared to $28.0 million for the quarter ended December 31, 2007. For the year ended December 31, 2008, selling, general and administrative expenses were $111.4 million, compared to $78.5 million for the year ended December 31, 2007. The increase in 2008 was primarily due to spending in connection with launch activities for LUVOX CR, including increased headcount and higher expenses to support the company's expanded sales force. The decrease in the fourth quarter of 2008 reflects a decrease in spending on LUVOX CR and reductions in headcount.

Jazz Pharmaceuticals' net loss for the quarter ended December 31, 2008 was $56.9 million, compared to a net loss of $60.0 million for the quarter ended December 31, 2007. For the year ended December 31, 2008, the net loss was $184.3 million, compared to a net loss of $138.8 million for the year ended December 31, 2007. Expenses for 2008 included a fourth quarter non-cash impairment charge of $29.8 million relating to the company's LUVOX CR intangible asset. Expenses for 2007 included a fourth quarter non-cash impairment charge of $20.2 million relating to the company's Antizol(R) (fomepizole) intangible asset; the rights to that product were sold to a third party during the third quarter of 2008. Net loss for 2008 also included increased interest expense, as compared with 2007, due primarily to the issuance of $40.0 million of additional senior secured notes in March 2008. Net loss for 2007 included a $17.5 million provision for the previously disclosed settlement of a government investigation of Orphan Medical.

Jazz Pharmaceuticals' cash, cash equivalents and marketable securities as of December 31, 2008 were $25.9 million, excluding restricted cash of $1.9 million. As previously disclosed, Jazz Pharmaceuticals did not make the $4.5 million interest payment due on December 31, 2008 on its outstanding $119.5 million principal amount of senior secured notes, and has received a notice of default from the noteholders. As a result of the default, the noteholders have the right, at any time, to accelerate the notes and require payment in full of the principal and interest, plus a pre-payment penalty. While Jazz Pharmaceuticals believes that its current cash resources, together with anticipated revenues from product sales, will be sufficient to fund its operations, they are not sufficient to fund both its operations and any payment of interest or repayment of principal on the notes. Jazz Pharmaceuticals is currently seeking a number of financing and strategic alternatives and is in discussions with the holders of the senior secured notes with respect to the December 31, 2008 interest payment default and the status of the notes. The report of the Jazz Pharmaceutical's independent registered public accounting firm on the company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2008 includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' ability to fund its operations on an ongoing basis, financing and strategic alternatives for the company, the status of the company's senior secured notes and potential partnering arrangements for certain of the company's programs. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the company's default on its senior secured notes, the right of the note holders to accelerate the obligations at any time, the company's potential need to seek protection under the provisions of the U.S. Bankruptcy Code in the event of an acceleration of the senior secured notes or otherwise and the resulting risk to the stockholders' receipt of any value for their shares; the company's need to raise additional funds; product sales and revenues; and the cost and results of product development and clinical trials. These and other risk factors are discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2008 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on March 26, 2009. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

                            JAZZ PHARMACEUTICALS, INC.
                       CONSOLIDATED STATEMENTS OF OPERATIONS
                     (In thousands, except per share amounts)
                                    (Unaudited)

                                        Three Months             Year
                                        Ended December        Ended December
                                             31,                  31,
                                        ---------------     -----------------
                                         2008      2007       2008       2007
                                         ----      ----       ----       ----
    Revenues:
      Product sales, net              $18,880   $14,860    $64,637    $53,536
      Royalties, net                      431       332      1,739      1,156
      Contract revenues                   284       285      1,138     10,611
                                          ---       ---      -----     ------
        Total revenues                 19,595    15,477     67,514     65,303

    Operating expenses:
      Cost of product sales             3,305     3,283     13,924      8,903
      Research and development         14,689    20,540     69,963     69,792
       Selling, general and
        administrative                 20,183    27,958    111,401     78,540
       Intangible asset
        amortization                    3,374     2,280     12,828      9,217
      Intangible asset impairment      29,763    20,160     29,763     20,160
       Provision for government
        settlement                          -         -          -     17,469
                                          ---       ---        ---     ------
        Total operating expenses       71,314    74,221    237,879    204,081
                                      -------   -------   --------   --------
    Loss from operations              (51,719)  (58,744)  (170,365)  (138,778)

      Interest income                     134     1,582      1,834      5,942
      Interest expense                 (5,365)   (3,554)   (19,742)   (13,647)
      Other income (expense)               10       (19)        16      1,797
       Gain on sale of product
        rights                              -       715      3,918      5,860
                                          ---       ---      -----      -----
        Net loss                     $(56,940) $(60,020) $(184,339) $(138,826)
                                     ========  ========  =========  =========

     Net loss per share, basic and
      diluted                          $(2.04)   $(2.53)    $(7.19)   $(10.04)
                                       ======    ======     ======    =======

      Weighted-average common
       shares used in computing
       net loss per share, basic and
        diluted                        27,948    23,694     25,646     13,829
                                       ======    ======     ======     ======



                            JAZZ PHARMACEUTICALS, INC.
                           SUMMARY OF PRODUCT SALES, NET
                                  (In thousands)
                                    (Unaudited)

                                                 Three Months
                                                Ended December    Year Ended
                                                      31,        December 31,
                                               ---------------  -------------
                                                  2008    2007    2008    2007
                                                  ----    ----    ----    ----
    Xyrem                                      $15,823 $11,120 $53,803 $39,018
    Luvox CR                                     3,057       -   5,728       -
    Antizol (1)                                      -   3,740   5,106  14,153
    Cystadane (2)                                    -       -       -     365
                                                   ---     ---     ---     ---
      Total                                    $18,880 $14,860 $64,637 $53,536
                                               ======= ======= ======= =======

    (1) The Company sold its rights to and interests in Antizol and Antizol-
        Vet in August 2008.
    (2) The Company sold its rights to and interests in Cystadane in March
        2007.



                      JAZZ PHARMACEUTICALS, INC.
                     CONSOLIDATED BALANCE SHEETS
                            (In thousands)
                             (Unaudited)
                                                   December 31,
                                                   ------------
                                                  2008      2007
                                                  ----      ----
                      ASSETS
    Current assets:
      Cash, cash equivalents and marketable
       securities                               $25,907  $102,945
      Restricted cash                             1,913     1,939
      Accounts receivable                         6,643     5,389
      Inventories                                 4,788     2,213
      Prepaid expenses                            2,366     3,224
      Other current assets                        2,382       381
                                                  -----       ---
        Total current assets                     43,999   116,091
    Property and equipment, net                   2,514     3,941
    Intangible assets, net                       32,526    36,040
    Goodwill                                     38,213    38,213
    Long-term restricted cash and investments         -    12,000
    Other long-term assets                          246     1,269
                                                    ---     -----
        Total assets                           $117,498  $207,554
                                               ========  ========

    LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
    Current liabilities:
      Line of credit                             $3,875    $3,459
      Senior secured notes                      118,534         -
      Accounts payable                            5,736     2,856
      Accrued liabilities                        19,024    29,047
      Purchased product rights liability         14,000         -
      Deferred revenue                           12,322     1,494
                                                 ------     -----
        Total current liabilities               173,491    36,856

    Non-current portion of deferred revenue      11,330    12,468
    Liability under government settlement        13,063    14,881
    Senior secured notes                              -    75,116
    Common stock subject to repurchase           12,492    13,241

    Stockholders' equity (deficit)              (92,878)   54,992
                                                -------    ------
    Total liabilities and stockholders'
     equity (deficit)                          $117,498  $207,554
                                               ========  ========




'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... ... 2016 , ... Georgia State University College of Law is ... Answering to the increasing demand for curricular specializations, the Certificate in Intellectual Property ... land use law. ,  , “The demand for lawyers with specific knowledge in ...
(Date:5/26/2016)... ... 2016 , ... There are nearly 14.5 million people living with and beyond ... Sunday, June 5, 2016, communities around the world will gather to recognize these cancer ... Cancer Survivors Day® is an annual worldwide Celebration of Life that is held on ...
(Date:5/26/2016)... ... ... effort to provide hair restoration information to the widest possible audience, Dr. Parsa Mohebi is ... the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making all of ... Mohebi says, “The positive response to the Snapchat videos we started last month has been ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... IRVINE, Calif. , May 25, 2016 /PRNewswire/ ... of testing for their new reference materials that ... workflows from sample collection to analyses. The rapid ... the demand for researchers to have standard methods ... data being generated. Biases inherently exist at every ...
Breaking Medicine Technology: